{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:35:50Z","timestamp":1780918550915,"version":"3.54.1"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>Impact<\/jats:title>\n            <jats:p>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>Immune persistence following primary vaccination with a single dose of meningococcal quadrivalent conjugate vaccines, MenACYW-TT\/MCV4-CRM, at age 10\u201312 years was demonstrated.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>Most participants primed with MenACYW-TT and MCV4-CRM maintained seroprotective titers against all serogroups, suggesting continued protection.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>Priming with MenACYW-TT resulted in higher persistent titers for serogroups C, W, and Y than MCV4-CRM.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>A MenACYW-TT booster induced a robust immune response; almost all participants achieved seroprotection against all serogroups.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>This analysis supports the ACIP recommendations for routine administration of a primary dose of a meningococcal ACWY conjugate vaccine at 11\u201312 years, with a booster dose at 16 years.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41390-024-03760-w","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T06:58:02Z","timestamp":1734073082000},"page":"1800-1802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10\u201312 years: phase III randomized trial complementary analysis of immune persistence 3\u20136 years after priming"],"prefix":"10.1038","volume":"97","author":[{"given":"James","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Galarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"Bchir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Zocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bertrand-Gerentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betzana","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"3760_CR1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41390-023-02478-5","volume":"94","author":"B Zambrano","year":"2023","unstructured":"Zambrano, B. et al. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study. Pediatr. Res. 94, 1035\u20131043 (2023).","journal-title":"Pediatr. Res."},{"key":"3760_CR2","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","volume":"38","author":"LJ Chang","year":"2020","unstructured":"Chang, L. J. et al. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine 38, 3560\u20133569 (2020).","journal-title":"Vaccine"},{"key":"3760_CR3","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","volume":"38","author":"MS Dhingra","year":"2020","unstructured":"Dhingra, M. S. et al. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Vaccine 38, 5194\u20135201 (2020).","journal-title":"Vaccine"},{"key":"3760_CR4","first-page":"1","volume":"62","author":"AC Cohn","year":"2013","unstructured":"Cohn, A. C. et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 62, 1\u201328 (2013).","journal-title":"MMWR Recomm. Rep."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03760-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03760-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03760-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T09:32:47Z","timestamp":1748511167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03760-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":4,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3760"],"URL":"https:\/\/doi.org\/10.1038\/s41390-024-03760-w","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.G., S.B., C.Z., I.B.-G., and B.Z. are Sanofi employees and may hold shares and\/or stock options in the company. J.P. reports no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}